SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-212531
Filing Date
2022-08-04
Accepted
2022-08-04 16:14:44
Documents
16
Period of Report
2022-08-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d371816d8k.htm   iXBRL 8-K 26564
2 EX-99.1 d371816dex991.htm EX-99.1 69670
3 EX-99.2 d371816dex992.htm EX-99.2 12401
7 GRAPHIC g371816dsp1.jpg GRAPHIC 5998
8 GRAPHIC g371816g23u42.jpg GRAPHIC 3024
  Complete submission text file 0001193125-22-212531.txt   257805

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA akba-20220804.xsd EX-101.SCH 2842
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20220804_lab.xml EX-101.LAB 17236
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20220804_pre.xml EX-101.PRE 10803
10 EXTRACTED XBRL INSTANCE DOCUMENT d371816d8k_htm.xml XML 3230
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 221136756
SIC: 2834 Pharmaceutical Preparations